Cooper Stock Price, News & Analysis

CooperCompanies (Nasdaq: COO) reported Q3 2025 financial results with revenue increasing 6% year-over-year to $1.06 billion. CooperVision revenue grew 6% to $718.4 million, while CooperSurgical revenue rose 4% to $341.9 million.

The company's GAAP diluted EPS decreased 6% to $0.49, while non-GAAP diluted EPS increased 15% to $1.10. Despite revenues below expectations, Cooper raised its earnings guidance, projecting improved revenue in Q4 and fiscal 2026. The company generated strong margins and robust free cash flow of $164.6 million.

During Q3, Cooper repurchased $52.1 million of common stock at an average price of $71.97. The company updated its fiscal 2025 guidance, expecting total revenue of $4,076-$4,096 million with organic growth of 4-4.5%, and non-GAAP diluted EPS of $4.08-$4.12.

CooperCompanies (Nasdaq: COO), a leading global medical device company, has announced its participation in the upcoming Wells Fargo Healthcare Conference. President and CEO Al White will represent the company in a session scheduled for September 3, 2025, at 3:00 PM ET.

Investors and interested parties can access the webcast through CooperCompanies' investor relations website at http://investor.coopercos.com.

CooperCompanies (Nasdaq: COO), a leading medical device company, has scheduled its third quarter 2025 financial results announcement for August 27, 2025, at 4:15 PM ET.

The company will host a conference call at 5:00 PM ET to discuss results and corporate developments. Investors can join via phone at 800-715-9871 (Conference ID: 3665386) or access the audio webcast through the company's investor relations website.

CooperCompanies (NYSE: COO) reported strong Q2 2025 financial results with revenue increasing 6% year-over-year to $1,002.3 million. The company's performance was driven by: - CooperVision revenue up 5% to $669.6 million - CooperSurgical revenue up 8% to $332.7 million - Non-GAAP diluted EPS of $0.96, up 14% from last year - Operating margin improved to 18% from 17% - Free cash flow of $18.1 million The company repurchased $40.6 million of common stock during Q2. Updated FY2025 guidance projects total revenue of $4,107-$4,146 million with organic growth of 5-6%, and non-GAAP diluted EPS of $4.05-$4.11.

CooperCompanies (NYSE: COO), a medical device company, has released its 2024 Sustainability Report highlighting the company's environmental and social initiatives. The report outlines key achievements in 2024, including: partnerships to reduce plastic usage, obtaining multiple sustainability certifications, and significant investments in employee development programs. The report maintains alignment with Sustainability Accounting Standards Board (SASB) Standards, demonstrating Cooper's commitment to investor-focused sustainability reporting. CEO Al White emphasized the company's dedication to enhancing people's lives while maintaining environmental responsibility.

CooperCompanies (Nasdaq: COO), a leading global medical device company, has announced its participation in the upcoming William Blair Growth Stock Conference. The company will be represented by Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, who will lead a session on Thursday, June 5, 2025, at 11:20 AM CT. Investors and interested parties can access the webcast through CooperCompanies' investor relations website at http://investor.coopercos.com.

The Canadian Association of Optometrists (CAO) has launched a new "GetEyeWise" public awareness campaign during Vision Health Month. The campaign, supported by provincial optometrist associations and industry sponsors Alcon and CooperVision (COO), aims to promote proactive eye health care. Currently, over 8 million Canadians live with eye diseases including AMD, Diabetic Retinopathy, cataracts, and glaucoma. Notably, 90% of vision loss cases in Canada can be prevented or treated if detected early. The CAO recommends comprehensive eye exams starting at 6-9 months of age, with specific frequency guidelines for different age groups. The campaign will run throughout May across multiple social media platforms in both English and French, emphasizing the importance of regular eye exams and highlighting optometrists' role as primary eye care providers.

CooperCompanies has appointed Barbara Carbone as an independent director to its Board of Directors, effective May 1, 2025. Carbone will also serve on the Audit Committee.

With nearly 40 years of experience, Carbone spent most of her career at KPMG (1981-2019), serving 24+ years as an Audit Partner. Her notable roles included Chairperson of the KPMG Partnership Audit Committee and National Partner in Charge for Human Resources. She also served on the KPMG Retired Partners Council from 2019-2022.

Currently, Carbone serves as Board Chairperson at TrueCar and holds board positions at Limoneira Company and Bob's Discount Furniture. She holds a B.S. in Business Administration from California State University at Sacramento. Bob Weiss, Chairman of CooperCompanies, welcomed her expertise in finance, accounting, leadership, and HR.

CooperCompanies (Nasdaq: COO) has scheduled its second quarter 2025 financial results announcement for Thursday, May 29, 2025, at 4:15 PM ET. The medical device company will follow the release with a conference call at 5:00 PM ET to discuss financial performance and corporate developments.

Interested parties can join the call using the following details:

• Dial-in number: 800-715-9871
• Conference ID: 1515103

An audio webcast will be available simultaneously, and a replay can be accessed through the company's investor relations website at http://investor.coopercos.com.